Endex 19

Hauptinformation

  • Handelsname:
  • Endex® 19,5% ad us. vet.[L], orale Suspension
  • Darreichungsform:
  • 5% ad us. vet.[L], orale Suspension
  • Verwenden für:
  • Tiere
  • Art der Medizin:
  • allopathic Droge

Dokumenten

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Endex® 19,5% ad us. vet.[L], orale Suspension
    Schweiz
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiegruppe:
  • Oral anwendbares Breitband-Anthelminthikum gegen Nematoden und Leberegelbefall bei Rindern

Weitere Informationen

Status

  • Quelle:
  • Institut für Veterinärpharmakologie
  • Zulassungsnummer:
  • Abgabekategorie
  • Letzte Änderung:
  • 22-01-2018

Packungsbeilage

Endex

19,5% ad us. vet.

, orale Suspension

Elanco Tiergesundheit AG

HINWEIS: momentan nicht lieferbar (Lieferengpass)!

Oral anwendbares Breitband-Anthelminthikum gegen Nematoden und

Leberegelbefall bei Rindern

ATCvet: QP52AE51

Zusammensetzung

1 ml Suspension enthält:

Wirkstoff: Triclabendazol 120 mg, Levamisolhydrochlorid 75 mg. Konservierungsmittel:

E 210, E 216, E 218. Antioxidantien: E 223. Excipiens ad suspensionem

Fachinformationen Wirkstoffe (CliniPharm)

Levamisol - Triclabendazol

Eigenschaften / Wirkungen

Levamisol wirkt gegen Nematoden und Triclabendazol gegen Leberegel. Der

Wirkmechanismus von Levamisol beruht auf der cholinergen Aktivität, die zu spastischen

Lähmungen der Nematoden führt. Ausserdem hemmt Levamisol die Fumarat-Reduktase.

Pharmakokinetik

Levamisol und Triclabendazol werden nach oraler Verabreichung rasch resorbiert. Das

resorbierte Triclabendazol wird sehr schnell zu Sulfoxiden und Sulfonen oxidiert. Maximale

Plasmakonzentrationen von Levamisol werden bereits nach 0,5 - 1 Stunde und für

Triclabendazol 24 - 36 Stunden nach der Verabreichung erreicht. Die Ausscheidung von

Levamisol erfolgt über den Urin und Kot und diejenige von Triclabendazol hauptsächlich

über den Kot.

Indikationen

Endex 19.5% eignet sich zur gleichzeitigen Behandlung reifer und sich entwickelnder

unreifer Stadien von Magenwürmern (Haemonchus, Ostertagia, T. axei), Darmwürmern

(Trichostrongylus, Cooperia, Nematodirus, Bunostomum, Oesophagostomum) und

Lungenwürmern (Dictyocaulus) sowie allen Formen der Infektion durch den grossen

Leberegel (frühe unreife, unreife und geschlechtsreife Stadien von Fasciola hepatica und

F. gigantica) bei Rindern.

Endex 19,5% wird oral mit Hilfe der üblichen Eingabegeräte oder einer Plastikspritze

verabreicht.

Empfohlene Dosis

12,0 mg Triclabendazol / kg Körpergewicht

7,5 mg Levamisolhydrochlorid / kg Körpergewicht

Praktische Dosierungsanleitung

1 ml/10 kg Körpergewicht.

Körpergewicht

Dosierung

50 kg

5,0 ml

100 kg

10,0 ml

150 kg

15,0 ml

200 kg

20,0 ml

250 kg

25,0 ml

300 kg

30,0 ml

für jeweils 50 kg mehr5,0 ml

Behandlungsprogramm

Endex 19.5% wird bei gleichzeitigem Befall mit Nematoden und grossem Leberegel

verabreicht.

Die Behandlung vor Beginn der Weidesaison beseitigt Würmer, die im Tier überwintert

haben und verhindert eine Verseuchung der Weide.

Die Behandlung während der Weidezeit eliminiert inzwischen erworbene Infektionen und

verringert die Kontamination der Weide mit Wurmeiern, die später zu Infektionen und

Erkrankungen führen würden.

Die Behandlung nach der Weideperiode wird empfohlen, um inzwischen neu erworbene

Infektionen zu eliminieren.

-Alle zugekauften Tiere sollten behandelt werden, bevor sie zur Herde stossen.

Anwendungseinschränkungen

Kontraindikationen

Das Produkt ist gegen geschlechtsreife Ostertagia-Stadien und sich entwickelnde Larven

wirksam. Es ist aber nicht zur Bekämpfung inhibierter Larven indiziert.

Vorsichtsmassnahmen

Keine.

Unerwünschte Wirkungen

VetVigilance: Pharmacovigilance-Meldung erstatten

Überdosierung kann zu vorübergehenden Nebenwirkungen führen (Muskelzittern,

Speichelfluss).

Essbare Gewebe: 28 Tage. Milch: 12 Tage, Behandlungen während der Trächtigkeit

sollten spätestens 7 Tage vor dem Abkalben erfolgen.

Wechselwirkungen

Keine bekannt.

Sonstige Hinweise

Nur für Tiere. Für Kinder unzugänglich aufbewahren. Nach Gebrauch Hände waschen.

Jegliche Verunreinigung mit dem Produkt oder dem leeren Behälter von stehenden und

fliessenden Gewässern sowie Wasserläufen vermeiden. Entleerte Behälter unschädlich

beseitigen. Bei Raumtemperatur (15 - 25°C) aufbewahren. Vor Feuchtigkeit, Frost und

Hitze schützen. Vor Gebrauch gut schütteln. Verabreichungsspritze vor und nach

Gebrauch gut reinigen.

Packungen

Flasche zu 800 ml.

Abgabekategorie: B

Swissmedic Nr. 51'377

Informationsstand: 03/2006

Dieser Text ist behördlich genehmigt.

27-4-2018

Ethnic Foods Inc. Issues Allergy Alert on Undeclared Peanuts in “Bhavnagri Mix”

Ethnic Foods Inc. Issues Allergy Alert on Undeclared Peanuts in “Bhavnagri Mix”

Ethnic Foods Inc. of 76 South Bayles Avenue, Port Washington, NY 11050, is recalling its 19 ounce package of Bhavnagri Mix snack mix because they may contain undeclared peanuts. People who have allergies to peanuts run the risk of serious or life-threatening allergic reaction if they consume these products.

FDA - U.S. Food and Drug Administration

19-7-2017

Enforcement Report for the Week of July 19, 2017

Enforcement Report for the Week of July 19, 2017

FDA - U.S. Food and Drug Administration

19-4-2017

Enforcement Report for the Week of April 19, 2017

Enforcement Report for the Week of April 19, 2017

FDA - U.S. Food and Drug Administration

2-2-2017

Receipt of clinical trial applications (CTA) summer 2017

Receipt of clinical trial applications (CTA) summer 2017

Due to summer holiday the Icelandic Medicines Agency (IMA) will not confirm receipt of clinical trial applications from 19 June to 14 August 2017.

IMA - Icelandic Medicines Agency

19-10-2016

Enforcement Report for the Week of October 19, 2016

Enforcement Report for the Week of October 19, 2016

FDA - U.S. Food and Drug Administration

19-8-2015

Enforcement Report for the Week of August 19, 2015

Enforcement Report for the Week of August 19, 2015

FDA - U.S. Food and Drug Administration

19-11-2014

Enforcement Report for the Week of November 19, 2014

Enforcement Report for the Week of November 19, 2014

FDA - U.S. Food and Drug Administration

19-3-2014

Enforcement Report for the Week of March 19, 2014

Enforcement Report for the Week of March 19, 2014

FDA - U.S. Food and Drug Administration

19-2-2014

Enforcement Report for the Week of February 19, 2014

Enforcement Report for the Week of February 19, 2014

FDA - U.S. Food and Drug Administration

17-2-2014

Danish Pharmacovigilance Update 19 December 2013

Danish Pharmacovigilance Update 19 December 2013

In this issue of Danish Pharmacovigilance Update: Patients with mechanical heart valves should not be treated with the new oral anticoagulants Pradaxa®, Xarelto® and Eliquis®.

Danish Medicines Agency

19-6-2013

Enforcement Report for the Week of June 19, 2013

Enforcement Report for the Week of June 19, 2013

FDA - U.S. Food and Drug Administration

19-12-2012

Enforcement Report for the Week of December 19, 2012

Enforcement Report for the Week of December 19, 2012

FDA - U.S. Food and Drug Administration

19-9-2012

Enforcement Report for the Week of September 19, 2012

Enforcement Report for the Week of September 19, 2012

FDA - U.S. Food and Drug Administration

4-7-2012

Danish Pharmacovigilance Update, 19 April 2012

Danish Pharmacovigilance Update, 19 April 2012

Among the topics covered in this issue of Danish Pharmacovigilance Update are: Split and crushed tablets containing finasteride may pose a risk for pregnant and fertile women.

Danish Medicines Agency

26-1-2012

Danish Pharmacovigilance Update, 19 January 2012

Danish Pharmacovigilance Update, 19 January 2012

In this issue of Danish Pharmacovigilance Update read about the risk that patients treated with statins develop diabetes, and proton-pump inhibitors (PPI) and the risk of hypomagnesaemia with long-term use.

Danish Medicines Agency

21-4-2010

Decision on future reimbursement status of losartan-containing medicines (C09CA01 and C09DA01) - angiotensin II antagonists

Decision on future reimbursement status of losartan-containing medicines (C09CA01 and C09DA01) - angiotensin II antagonists

On 16 April 2010, the Danish Medicines Agency decided on the future reimbursement status of some of the losartan-containing medicines in ATC groups C09C and C09D, making these products eligible for general reimbursement as of 19 April 2010.

Danish Medicines Agency

21-11-2008

Consultation responses on the future reimbursement status of medicinal products for cardiovascular diseases

Consultation responses on the future reimbursement status of medicinal products for cardiovascular diseases

The Reimbursement Committee’s additional recommendation concerning the future reimbursement status of medicinal products for cardiovascular diseases in ATC groups C02, C03, C07, C08 and C09 (antihypertensives) was submitted for consultation with 19 September 2008 as the consultation deadline

Danish Medicines Agency

18-12-2006

Reassessment of ATC-groups C01, C04 and C05

Reassessment of ATC-groups C01, C04 and C05

At its meeting on 19 September 2006, the Reimbursement Committee had its first discussion of the reimbursement status of the following ATC groups.

Danish Medicines Agency

18-7-2018

Agenda:  Agenda - CVMP agenda of the 17-19 July 2018 meeting

Agenda: Agenda - CVMP agenda of the 17-19 July 2018 meeting

Committee for Medicinal Products for Veterinary Use - Draft agenda of July 2018 meeting

Europe - EMA - European Medicines Agency

17-7-2018

Agenda:  Agenda - COMP agenda of the 17-19 July 2018 meeting

Agenda: Agenda - COMP agenda of the 17-19 July 2018 meeting

Draft agenda for the meeting on 17-19 July 2018

Europe - EMA - European Medicines Agency

28-6-2018

 Minutes of the COMP meeting of 17-19 April 2018

Minutes of the COMP meeting of 17-19 April 2018

Europe - EMA - European Medicines Agency

22-6-2018

News and press releases:  Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19–21 June 2018

News and press releases: Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19–21 June 2018

First stem cell-based veterinary medicine recommended for marketing authorisation

Europe - EMA - European Medicines Agency

22-6-2018

News and press releases:  Reinforced EU/US collaboration on medicines

News and press releases: Reinforced EU/US collaboration on medicines

Update on the European Commission/EMA–FDA bilateral of 18-19 June 2018

Europe - EMA - European Medicines Agency

19-6-2018

Zerbaxa (Merck Sharp and Dohme B.V.)

Zerbaxa (Merck Sharp and Dohme B.V.)

Zerbaxa (Active substance: ceftolozane / tazobactam) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3914 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3772/T/17

Europe -DG Health and Food Safety

19-6-2018

SOLYMBIC (Amgen Europe B.V.)

SOLYMBIC (Amgen Europe B.V.)

SOLYMBIC (Active substance: adalimumab) - Centralised - Withdrawal - Commission Decision (2018)3913 of Tue, 19 Jun 2018

Europe -DG Health and Food Safety

19-6-2018

Zepatier (Merck Sharp and Dohme B.V.)

Zepatier (Merck Sharp and Dohme B.V.)

Zepatier (Active substance: elbasvir / grazoprevir) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3917 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4126/T/15

Europe -DG Health and Food Safety

19-6-2018

Maviret (AbbVie Deutschland GmbH and Co. KG)

Maviret (AbbVie Deutschland GmbH and Co. KG)

Maviret (Active substance: glecaprevir / pibrentasvir) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3916 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4430/T/11

Europe -DG Health and Food Safety

19-6-2018

Insuman (Sanofi-Aventis Deutschland GmbH)

Insuman (Sanofi-Aventis Deutschland GmbH)

Insuman (Active substance: human insulin) - Centralised - Yearly update - Commission Decision (2018)3889 of Tue, 19 Jun 2018

Europe -DG Health and Food Safety

19-6-2018

Aftovaxpur Doe (Merial)

Aftovaxpur Doe (Merial)

Aftovaxpur Doe (Active substance: purified, inactivated foot-and-mouth disease virus strains O1 Manisa, O1 BFS, O Taiwan 3/97, A22 Iraq, A24 Cruzeiro, A Turkey 14/98, Asia 1 Shamir, SAT2 Saudi Arabia) - Centralised - Renewal - Commission Decision (2018)3891 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2292/R/8

Europe -DG Health and Food Safety

19-6-2018

Dany's BienenWohl (Dany Bienenwohl GmbH)

Dany's BienenWohl (Dany Bienenwohl GmbH)

Dany's BienenWohl (Active substance: oxalic acid dihydrate) - Centralised - Authorisation - Commission Decision (2018)3892 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/4667

Europe -DG Health and Food Safety

19-6-2018

Iscover (Sanofi-Aventis groupe)

Iscover (Sanofi-Aventis groupe)

Iscover (Active substance: Clopidogrel) - Centralised - Yearly update - Commission Decision (2018)3888 of Tue, 19 Jun 2018

Europe -DG Health and Food Safety

19-6-2018

Lusduna (Merck Sharp and Dohme B.V.)

Lusduna (Merck Sharp and Dohme B.V.)

Lusduna (Active substance: insulin glargine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3918 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4101/T/6

Europe -DG Health and Food Safety

19-6-2018

ZINPLAVA (Merck Sharp and Dohme B.V.)

ZINPLAVA (Merck Sharp and Dohme B.V.)

ZINPLAVA (Active substance: bezlotoxumab) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3915 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4136/T/11

Europe -DG Health and Food Safety

19-6-2018

Aerinaze (Merck Sharp and Dohme Limited)

Aerinaze (Merck Sharp and Dohme Limited)

Aerinaze (Active substance: desloratadine; pseudoephedrine sulphate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3930 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/772/T/37

Europe -DG Health and Food Safety

19-6-2018

Neoclarityn (Merck Sharp and Dohme Limited)

Neoclarityn (Merck Sharp and Dohme Limited)

Neoclarityn (Active substance: desloratadine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3931 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/314/T/88

Europe -DG Health and Food Safety

19-6-2018

Onbrez Breezhaler (Novartis Europharm Limited)

Onbrez Breezhaler (Novartis Europharm Limited)

Onbrez Breezhaler (Active substance: indacaterol) - Corrigendum - Commission Decision (2018)2573 of Tue, 19 Jun 2018

Europe -DG Health and Food Safety

19-6-2018

Orgalutran (Merck Sharp and Dohme Limited)

Orgalutran (Merck Sharp and Dohme Limited)

Orgalutran (Active substance: ganirelix) - Corrigendum - Commission Decision (2017)2520 of Tue, 19 Jun 2018

Europe -DG Health and Food Safety

19-6-2018

Invirase (Roche Registration GmbH)

Invirase (Roche Registration GmbH)

Invirase (Active substance: Saquinavir) - Corrigendum - Commission Decision (2018)1950 of Tue, 19 Jun 2018

Europe -DG Health and Food Safety

19-6-2018

Xyrem (UCB Pharma S.A.)

Xyrem (UCB Pharma S.A.)

Xyrem (Active substance: Sodium oxybate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3912 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/593/T/74

Europe -DG Health and Food Safety

19-6-2018

Agenda:  Agenda - CVMP agenda of the 19-21 June 2018 meeting

Agenda: Agenda - CVMP agenda of the 19-21 June 2018 meeting

Europe - EMA - European Medicines Agency

18-6-2018

Agenda:  Agenda - COMP agenda of the 19-21 June 2018 meeting

Agenda: Agenda - COMP agenda of the 19-21 June 2018 meeting

Committee for Orphan Medicinal Products (COMP) draft agenda for the meeting on 19-21 June 2018

Europe - EMA - European Medicines Agency

11-6-2018

TAGRISSO (AstraZeneca AB)

TAGRISSO (AstraZeneca AB)

TAGRISSO (Active substance: osimertinib) - Centralised - 2-Monthly update - Commission Decision (2018)3757 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4124/II/19

Europe -DG Health and Food Safety

8-6-2018

Fees and charges: summary - from 1 July 2018

Fees and charges: summary - from 1 July 2018

A summary of the fees and charges for the financial year 2018-19 is now available

Therapeutic Goods Administration - Australia

31-5-2018

 Minutes of the CHMP meeting 19-22 March 2018

Minutes of the CHMP meeting 19-22 March 2018

Europe - EMA - European Medicines Agency

30-5-2018

 Minutes of the CVMP meeting of 17–19 April 2018

Minutes of the CVMP meeting of 17–19 April 2018

Europe - EMA - European Medicines Agency

30-5-2018

 Minutes of the CVMP meeting of 17-19 April 2018

Minutes of the CVMP meeting of 17-19 April 2018

Europe - EMA - European Medicines Agency

28-5-2018

Vipidia (Takeda Pharma A/S)

Vipidia (Takeda Pharma A/S)

Vipidia (Active substance: alogliptin) - Centralised - Renewal - Commission Decision (2018)3345 of Mon, 28 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2182/R/19

Europe -DG Health and Food Safety

21-5-2018

EU/3/07/522 (Best Regulatory Consulting Ltd)

EU/3/07/522 (Best Regulatory Consulting Ltd)

EU/3/07/522 (Active substance: (manganese, dichloro [(4aR, 13aR, 17aR, 21aR)-1, 2, 3, 4, 4a, 5, 6, 12, 13, 13a, 14, 15, 16, 17, 17a, 18, 19, 20, 21, 21a-eicosahydro-11, 7-nitrilo-7H-dibenzo[ b,h] [1,4,7,10] tetraazacycloheptadecine-?N5, ?N13, ?N18, ?N21, ?N22]-)) - Transfer of orphan designation - Commission Decision (2018)3136 of Mon, 21 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/089/07/T/01

Europe -DG Health and Food Safety

16-5-2018

Docetaxel Kabi (Fresenius Kabi Deutschland GmbH)

Docetaxel Kabi (Fresenius Kabi Deutschland GmbH)

Docetaxel Kabi (Active substance: Docetaxel) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3053 of Wed, 16 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2325/T/19

Europe -DG Health and Food Safety

20-4-2018

Pending EC decision:  Credelio, lotilaner, Opinion date: 19-Apr-2018

Pending EC decision: Credelio, lotilaner, Opinion date: 19-Apr-2018

Europe - EMA - European Medicines Agency